ATRA · Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Cap structure and valuation

Cap structure
SP	$8.78
SO	8.2M
Options	5.2M
Warrants	6.4M
FD SO	19.8M
MC	$173.8M

Cash	$8.5M
Total debt	—
EV	$165.3M

TTM Multiples
EV / Revenue	7.1x
EV / EBITDA	—
MC / Net Income	—
EV / FCF	—
MC / FCF	—

MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-03-10. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative.

Financial statements

	3/31/26	12/31/25	9/30/25	6/30/25
Total Revenue	0.52	1.59	3.45	17.57
Revenue YoY %	(99.5%)	(95.1%)	(91.4%)	(38.6%)

SG&A	3.60	4.28	3.99	6.51
R&D	0.16	(0.22)	2.92	7.31

Operating Income	(3.37)	(2.56)	(3.57)	3.20
Operating Income YoY %	(108.7%)	79.0%	83.6%	117.5%
Operating Margin %	(652.9%)	(160.7%)	(103.5%)	18.2%
EBITDA	(3.34)	(2.51)	(3.54)	3.43
EBITDA Margin %	(647.3%)	(157.6%)	(102.5%)	19.5%

Interest Expense	0.83	0.89	0.91	0.97
Pretax Income	(4.14)	(3.41)	(4.28)	2.39
Tax Provision	0.00	0.00	0.03	0.00
Net Income	(4.14)	(3.41)	(4.30)	2.39
Net Margin %	(803.3%)	(213.5%)	(124.6%)	13.6%

Diluted EPS	-$0.29	-$0.36	-$0.32	$0.19
Basic EPS	-$0.29	-$0.35	-$0.32	$0.20
Diluted Avg Shares	14.1	0.4	13.6	12.3
Basic Avg Shares	14.1	0.4	13.6	12.2

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Total Revenue	23.14	120.77	128.94	8.57	63.57
Revenue YoY %	(80.8%)	(6.3%)	1404.0%	(86.5%)	—

SG&A	18.38	26.25	39.89	50.91	71.55
R&D	10.18	37.45	151.48	224.78	272.53

Operating Income	(6.31)	35.86	(83.44)	(276.01)	(280.51)
Operating Income YoY %	(117.6%)	143.0%	69.8%	1.6%	—
Operating Margin %	(27.3%)	29.7%	(64.7%)	(3219.5%)	(441.2%)
EBITDA	(5.96)	37.98	(78.39)	(271.18)	(274.86)
EBITDA Margin %	(25.8%)	31.4%	(60.8%)	(3163.2%)	(432.4%)

Interest Expense	3.60	3.79	4.62	5.29	0.37
Pretax Income	(9.44)	32.72	(85.42)	(276.11)	(228.29)
Tax Provision	0.03	0.03	(0.01)	0.01	0.01
Net Income	(9.47)	32.69	(85.40)	(276.13)	(228.30)
Net Margin %	(40.9%)	27.1%	(66.2%)	(3220.9%)	(359.1%)

Diluted EPS	-$0.78	$2.57	-$11.41	-$65.19	-$2.24
Basic EPS	-$0.76	$2.61	-$11.41	-$65.19	-$2.24
Diluted Avg Shares	14.1	12.7	7.5	4.2	102.0
Basic Avg Shares	14.1	12.5	7.5	4.2	102.0

	3/31/26	12/31/25	9/30/25	6/30/25
Cash & Equivalents	8.36	8.48	5.74	16.90
Receivables	0.00	1.25	1.91	0.00
Inventory	—	0.00	0.00	0.00
Total Current Assets	12.17	12.21	18.43	24.77

Net PPE	0.06	0.07	0.15	0.18
Total Assets	20.00	20.23	30.17	36.90

Accounts Payable	0.64	0.13	0.32	1.76
Total Current Liabilities	5.64	14.92	18.06	14.56
Total Liabilities	57.31	58.74	66.80	71.94

Retained Earnings	(2,026.01)	(2,021.87)	(2,018.46)	(2,014.16)
Total Equity	(37.31)	(38.50)	(36.63)	(35.04)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Cash & Equivalents	8.36	8.48	25.03	25.84	92.94
Receivables	0.00	1.25	1.48	34.11	40.22
Inventory	—	0.00	10.65	9.71	1.59
Total Current Assets	12.17	12.21	64.89	101.87	295.08

Net PPE	0.06	0.07	1.29	3.86	6.30
Total Assets	20.00	20.23	109.10	165.50	376.42

Accounts Payable	0.64	0.13	4.37	3.68	6.87
Total Current Liabilities	5.64	14.92	134.57	142.23	78.92
Total Liabilities	57.31	58.74	206.38	264.74	249.78

Retained Earnings	(2,026.01)	(2,021.87)	(2,054.55)	(1,969.15)	(1,693.02)
Total Equity	(37.31)	(38.50)	(97.28)	99.23	126.64

	3/31/26	12/31/25	9/30/25	6/30/25
Net Income	(4.14)	(3.41)	(4.30)	2.39
D&A	0.03	0.05	0.04	0.24
Stock-Based Comp	0.75	1.52	1.23	2.80
Operating Cash Flow	(3.07)	(5.70)	(9.79)	(7.32)

CapEx	—	0.00	0.00	0.00
Investing Cash Flow	0.00	8.44	(2.42)	(5.07)

Stock Issuance	2.95	(0.03)	1.50	0.00
Financing Cash Flow	2.95	(0.00)	1.05	15.30

Free Cash Flow	—	(5.70)	(9.79)	(7.32)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Net Income	(9.47)	32.69	(85.40)	(276.13)	(228.30)
D&A	0.35	2.12	5.05	4.83	5.65
Stock-Based Comp	6.29	9.75	27.00	45.39	53.84
Operating Cash Flow	(25.88)	(50.94)	(68.72)	(192.98)	(270.43)

CapEx	—	0.00	(0.25)	(1.22)	(4.19)
Investing Cash Flow	0.95	18.15	8.62	123.87	202.96

Stock Issuance	4.42	1.47	9.35	2.14	21.89
Financing Cash Flow	19.30	16.10	59.28	2.01	53.08

Free Cash Flow	—	(50.94)	(68.96)	(194.20)	(274.62)

	3/31/26	12/31/25	9/30/25	6/30/25
Current Ratio	2.16	0.82	1.02	1.70
Quick Ratio	—	0.82	1.02	1.70
Debt / Equity	-1.54	-1.53	-1.82	-2.05
EBITDA Margin %	(647.3%)	(157.6%)	(102.5%)	19.5%
Working Capital	6.53	(2.71)	0.38	10.21
Net Debt	—	—	—	—
ROE %	11.1%	8.8%	11.7%	(6.8%)
ROA %	(20.7%)	(16.8%)	(14.3%)	6.5%

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Current Ratio	2.16	0.82	0.48	0.72	3.74
Quick Ratio	—	0.82	0.40	0.65	3.72
Debt / Equity	-1.54	-1.53	-2.12	2.67	1.97
EBITDA Margin %	(25.8%)	31.4%	(60.8%)	(3163.2%)	(432.4%)
Working Capital	6.53	(2.71)	(69.68)	(40.36)	216.16
Net Debt	—	—	—	—	—
ROE %	25.4%	(84.9%)	87.8%	(278.3%)	(180.3%)
ROA %	(47.3%)	161.5%	(78.3%)	(166.8%)	(60.7%)

Insider activity (last 2 years)

Date Filed	Reporter	Relationship	Trans. Date	Code	Shares	Price	Total Value
2026-05-11	Panacea Innovation Ltd	10% Owner	2026-05-07	S	(313,446)	$10.10	-$3,165,021
2026-05-11	EcoR1 Capital, LLC	10% Owner	2026-05-07	P	507,407	$9.35	$4,744,255
2026-03-19	Panacea Innovation Ltd	10% Owner	2026-03-17	M	259,163	$0.00	$26
2026-03-19	Panacea Innovation Ltd	10% Owner	2026-03-17	F	(5)	$5.23	-$26
2026-03-19	Panacea Innovation Ltd	10% Owner	2026-03-17	M	(259,163)	$6.61	-$1,713,042
2026-03-11	Nguyen AnhCo	Director, Officer (President and CEO)	2026-03-09	A	81,100	—	$0
2026-03-11	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2026-03-09	A	20,300	—	$0
2026-03-04	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2026-03-02	S	(24)	$5.08	-$122
2026-03-04	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2026-03-02	S	(1,603)	$5.08	-$8,145
2026-03-04	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2026-03-02	S	(377)	$5.08	-$1,916
2026-03-04	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2026-03-02	S	(100)	$5.08	-$508
2026-03-04	Nguyen AnhCo	Director, Officer (President and CEO)	2026-03-02	S	(198)	$5.08	-$1,006
2026-03-04	Nguyen AnhCo	Director, Officer (President and CEO)	2026-03-02	S	(58)	$5.08	-$295
2026-03-04	Nguyen AnhCo	Director, Officer (President and CEO)	2026-03-02	S	(1,298)	$5.09	-$6,602
2026-03-04	Nguyen AnhCo	Director, Officer (President and CEO)	2026-03-02	S	(1,442)	$5.09	-$7,335
2026-01-14	Panacea Innovation Ltd	10% Owner	2026-01-12	S	(80,554)	$6.07	-$489,019
2025-12-01	Panacea Innovation Ltd	10% Owner	2025-11-28	M	48,737	$0.00	$5
2025-12-01	Panacea Innovation Ltd	10% Owner	2025-11-28	F	(1)	$14.03	-$14
2025-12-01	Panacea Innovation Ltd	10% Owner	2025-11-28	M	(48,737)	$6.61	-$322,147
2025-11-19	Nguyen AnhCo	Director, Officer (President and CEO)	2025-11-17	S	(2,859)	$13.19	-$37,699
2025-11-19	Nguyen AnhCo	Director, Officer (President and CEO)	2025-11-17	S	(56)	$13.19	-$739
2025-11-19	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2025-11-17	S	(1,645)	$13.19	-$21,691
2025-11-19	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2025-11-17	S	(85)	$13.19	-$1,121
2025-11-19	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2025-11-17	S	(74)	$13.19	-$976
2025-08-20	Nguyen AnhCo	Director, Officer (President and CEO)	2025-08-18	S	(57)	$11.61	-$662
2025-08-20	Nguyen AnhCo	Director, Officer (President and CEO)	2025-08-18	S	(1,281)	$11.62	-$14,879
2025-08-20	Nguyen AnhCo	Director, Officer (President and CEO)	2025-08-18	S	(1,620)	$11.62	-$18,820
2025-08-20	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2025-08-18	S	(55)	$11.61	-$638
2025-08-20	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2025-08-18	S	(86)	$11.61	-$999
2025-08-20	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2025-08-18	S	(1,668)	$11.61	-$19,372
2025-08-19	Panacea Innovation Ltd	10% Owner	2025-08-15	P	55,000	$12.19	$670,422
2025-07-21	Panacea Innovation Ltd	10% Owner	2025-07-17	P	19,335	$9.64	$186,372
2025-06-12	Gallagher Carol Giltner	Director	2025-06-10	A	7,828	—	$0
2025-06-12	Fust Matthew K	Director	2025-06-10	A	7,828	—	$0
2025-06-12	Touchon Pascal	Director	2025-06-10	A	7,828	—	$0
2025-06-12	Roncarolo Maria Grazia	Director	2025-06-10	A	7,828	—	$0
2025-06-12	MALLIK AMEET	Director	2025-06-10	A	7,828	—	$0
2025-06-12	HEIDEN WILLIAM K	Director	2025-06-10	A	7,828	—	$0
2025-05-20	Grant-Huerta Yanina	Officer (Chief Accounting Officer)	2025-05-16	S	(2,218)	$6.76	-$15,000
2025-05-20	Nguyen AnhCo	Director, Officer (President and CEO)	2025-05-16	S	(3,276)	$6.76	-$22,156
2025-05-16	Adiumentum Capital Fund I LP	Director, 10% Owner, Other (See remarks)	2025-05-16	A	75,572	$6.61	$499,531
2025-05-16	Adiumentum Capital Fund I LP	Director, 10% Owner, Other (See remarks)	2025-05-16	A	227,000	$6.61	$1,500,447
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(1,900)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(460)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(496)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(154)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(381)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(350)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(262)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(543)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(331)	—	$-0
2025-04-02	Hyllengren Eric J	Other (Former EVP, CFO & COO)	2025-03-31	D	(8,961)	—	$-0
2025-03-05	Nguyen AnhCo	Director, Officer (President and CEO)	2025-03-03	S	(3,331)	$7.00	-$23,307
2025-03-05	Hyllengren Eric J	Officer (EVP, CFO and COO)	2025-03-03	S	(1,211)	$7.00	-$8,473
2025-03-05	Henrich Jill	Officer (EVP, Chief Regulatory Officer)	2025-03-03	S	(1,059)	$7.00	-$7,410
2025-01-29	Hyllengren Eric J	Officer (EVP, CFO and COO)	2025-01-27	A	34,050	—	$0
2024-11-20	Henrich Jill	Officer (EVP, Chief Regulatory Officer)	2024-11-18	S	(1,000)	$11.20	-$11,198
2024-11-20	Hyllengren Eric J	Officer (EVP, CFO and COO)	2024-11-18	S	(1,364)	$11.20	-$15,274
2024-11-20	Nguyen AnhCo	Director, Officer (President and CEO)	2024-11-18	S	(1,664)	$11.20	-$18,633
2024-09-11	Nguyen AnhCo	Director, Officer (President and CEO)	2024-09-09	A	45,000	—	$0
2024-08-20	Touchon Pascal	Director, Officer (President and CEO)	2024-08-16	S	(2,762)	$6.63	-$18,309
2024-08-20	Touchon Pascal	Director, Officer (President and CEO)	2024-08-16	S	(276)	$6.63	-$1,830
2024-08-20	Nguyen AnhCo	Officer (EVP, Chief Sci. & Tech Officer)	2024-08-16	S	(1,468)	$6.63	-$9,731
2024-08-20	Nguyen AnhCo	Officer (EVP, Chief Sci. & Tech Officer)	2024-08-16	S	(297)	$6.63	-$1,969
2024-08-20	Nguyen AnhCo	Officer (EVP, Chief Sci. & Tech Officer)	2024-08-16	S	(56)	$6.63	-$371
2024-08-20	Murugan Amar	Officer (EVP, Chief Legal Officer)	2024-08-16	S	(877)	$6.63	-$5,814
2024-08-20	Murugan Amar	Officer (EVP, Chief Legal Officer)	2024-08-16	S	(192)	$6.63	-$1,273
2024-08-20	Murugan Amar	Officer (EVP, Chief Legal Officer)	2024-08-16	S	(89)	$6.63	-$590
2024-08-20	Hyllengren Eric J	Officer (EVP, CFO)	2024-08-16	S	(1,041)	$6.63	-$6,901
2024-08-20	Hyllengren Eric J	Officer (EVP, CFO)	2024-08-16	S	(29)	$6.63	-$192
2024-08-20	Henrich Jill	Officer (EVP, Global Head RA & Quality)	2024-08-16	S	(831)	$6.63	-$5,509
2024-08-20	Henrich Jill	Officer (EVP, Global Head RA & Quality)	2024-08-16	S	(132)	$6.63	-$875
2024-08-14	Touchon Pascal	Director, Officer (President and CEO)	2024-08-12	D	(9,000)	—	$-0
2024-08-14	Touchon Pascal	Director, Officer (President and CEO)	2024-08-12	D	(9,680)	—	$-0
2024-08-14	Touchon Pascal	Director, Officer (President and CEO)	2024-08-12	D	(7,075)	—	$-0
2024-05-20	Touchon Pascal	Director, Officer (President and CEO)	2024-05-16	S	(81,506)	$0.62	-$50,289
2024-05-20	Nguyen AnhCo	Officer (EVP, Chief Sci. & Tech Officer)	2024-05-16	S	(42,899)	$0.62	-$26,469
2024-05-20	Murugan Amar	Officer (EVP, Chief Legal Officer)	2024-05-16	S	(32,401)	$0.62	-$19,991
2024-05-20	Hyllengren Eric J	Officer (EVP, CFO)	2024-05-16	S	(28,648)	$0.62	-$17,676
2024-05-20	Henrich Jill	Officer (EVP, Global Head RA & Quality)	2024-05-16	S	(25,750)	$0.62	-$15,888